Benign in Medical Technology

YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB PRESENTATIONS TO BE MADE AT THE 100TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH AND EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY

... marketed antibodies. Consequently, nimotuzumab's benign safety profile makes it the anti-EGFR agent of ... transient monovalent binding that results in its benign safety profile. Both antibodies bind definitively ... developers worldwide aimed at explaining the benign toxicity profile of nimotuzumab given its ...

Light Sciences Oncology Raises $40.1 Million in Series C Financing

... Cancer and Phase I/II and Phase IIa benign Prostatic Hyperplasia Studies BELLEVUE, Wash., ... and early stage clinical trials in benign prostatic hyperplasia (BPH). "We are ... of the versatile Litx platform to include benign neoplasms such as benign prostatic hyperplasia ...

Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder

... silodosin, an investigational treatment for benign prostatic hyperplasia (BPH, or prostate ... US for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH). About Oxybutynin ... a product under development for the treatment of benign prostatic hyperplasia; a six-month formulation of ...

Vermillion's Biomarkers Prove Beneficial in Identifying Women With Ovarian Cancer and Detecting Early-Stage Disease

... of our biomarkers to distinguish between benign and malignant tumors and diagnose early-stage ... that it can distinguish malignant tumors from benign pelvic masses. Results of the study demonstrated ... useful biomarkers for ovarian cancer. Fluids from benign (n=45), malignant (n=15), and low malignant ...

Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale d'Urologie

... the Company's drug candidate for the treatment of benign prostatic hypertrophy (BPH), at the 29th Congress ... Spectrum is developing ozarelix for benign prostatic hypertrophy (BPH), hormone-dependent prostate cancer and other indications. About benign Prostatic Hypertrophy ...

Neurocrine Biosciences Presents Elagolix Data

... with a GnRH antagonist may constitute a new paradigm for the treatment of benign prostatic hyperplasia. About Endometriosis Endometriosis is a ... irritable bowel syndrome (IBS), anxiety, depression, pain, diabetes, benign prostatic hyperplasia (BPH) and other neurological and endocrine related ...

Dendreon Presents Preclinical Data Demonstrating Activity of TRPM8 Agonist, D-3263, in Benign Prostatic Hyperplasia

... which targets TRPM8 (a transmembrane cation channel protein), to treat benign prostatic hyperplasia (BPH). D-3263 demonstrated the ability to reduce ... "Preclinical Evaluation of the TRPM8 Ion Channel Agonist D-3263 for benign Prostatic Hyperplasia" is being presented at the American Urological ...

ExonHit Reports Proof-of-Concept in Breast Cancer Diagnostic Using its SpliceArray(TM) Platform

... data demonstrate that exons are differently expressed in malignant and benign lesions, and alternative transcripts determine the molecular ... P, Delaloge S. Exonic expression profiling of breast cancer and benign lesions: a retrospective analysis. The Lancet Oncology, Early ...

Metastatic Bone Disease Patients Can Walk in Lazarus' Footsteps

... pain regression for individuals with both painful bone metastases and benign lytic lesions that didn't respond to conventional analgesic treatment. ... Osteolytic Lesions -- Personal Experience in 81 Patients Treated for benign Diseases and Metastases," G. Anselmetti, G. Chiara, M. Liotti, M. ...

Researchers Discover Metabolite Linked to Aggressive Prostate Cancer

... metabolites across 262 samples of tissue, blood or urine associated with benign prostate tissue, early stage prostate cancer and advanced, or metastatic, ... about 10 that were present more often in prostate cancer than in the benign cells and were present most often in the advanced cancer samples. ...

Vermillion Presents Critical Data From Its OVA1 Clinical Trial

... study entitled "A biomarker panel for distinguishing between malignant and benign ovarian tumors" was co-authored by Fred Ueland, MD, Associate Professor of ... attached link "A biomarker panel for distinguishing between malignant and benign ovarian tumors." The primary aim of the study was to determine the ...

Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma

... action of Litx treatment, additional applications of Litx may also include benign neoplasms--growths of non-cancerous tissue that nonetheless have ... LSO has completed a Phase 1/2 trial and has initiated a Phase 2a trial in benign prostatic hyperplasia (BPH), or enlargement of the prostate. The company ...

Vermillion Renews Strategic Alliance Agreement With Quest Diagnostics, Inc.

... presentation, "A Biomarker Panel for Distinguishing Between Malignant and benign Ovarian Tumors" was co-authored by scientists at Vermillion, Dr. Fred ... addition to developing a diagnostic test designed to distinguish between benign and malignant pelvic masses, Vermillion has a broad program of ovarian ...

Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin

... in metastatic cancer patients. The trial also confirmed Alpharadin's benign side-effect profile and, importantly for a drug in this clinical setting, ... study has also further confirmed the safety of Alpharadin and shown its benign side-effect profile. In fact, the higher the dose of Alpharadin that ...

Research Explains How Advanced Prostate Cancer Becomes Resistant to Androgen-Deprivation Therapy

... castrate men (collected immediately after death via rapid autopsy) than in benign and cancerous prostate tissue in men with normal circulating androgen ... in the nation. For control purposes, the researchers also examined benign and cancerous prostate tissue from eight men who underwent radical ...

Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia

... (a transmembrane cation channel protein also known as Trp-M8), to treat benign prostatic hyperplasia (BPH). The abstract (#2041), "Preclinical Validation of the Trp-p8 Ion Channel as a Target for benign Prostatic Hyperplasia," is being presented at the American Urological ...

Preventing Prostate Cancer and BPH: Prostate-Health Expert Available (National Men's Health Week Is June 9-15)

... -- The risk of the two major prostate diseases, cancer and benign prostatic hyperplasia (BPH), can be reduced by changes in lifestyle, such ... protein have a significantly lower risk of developing symptomatic benign prostatic hyperplasia, or BPH, a condition associated with frequent ...

Vermillion Receives Award From the Society of Gynecologic Oncologists

... "Prospective independent validation of a marker panel for distinguishing benign from malignant pelvic masses." The abstract, which demonstrated that the ... Cancer Center -- Validation of a Marker Panel for Distinguishing between benign and Malignant Pelvic Masses Collaborators: The Danish Cancer ...

Vantia Therapeutics' Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in Nocturia

... (defined as waking to void at night) is a common condition, with prevalence increasing markedly with age. It is often the presenting symptom of benign prostatic hypertrophy (BPH) with at least 70% of BPH patients complaining of nocturia. Whilst some symptoms of BPH are successfully addressed by the ...

BioVex to Report Phase I/II Clinical Trial Results for the Front Line Treatment of Head and Neck Cancer With OncoVEX GM-CSF at the 2009 American Society of Clinical Oncology Meeting

... to become a leading standard of care in the treatment of many solid tumors based on the strength of clinical data generated to date, coupled with a benign side effect profile. Previous clinical trials have enrolled patients with breast cancer, melanoma, and pancreatic cancer in addition to head and neck ...

Moffitt Cancer Center Signs Licensing Agreement with Frantz BioMarkers, LLC

... tool or method for accurate diagnosis without surgery. Even among symptomatic women, surgery is the only reliable way to distinguish between benign and malignant disease. It is estimated that up to 5 percent of women in the United States will undergo surgery for a suspected ovarian neoplasm. ...

Study Results Present Paradigm Shift; REDUCE Trial Shows New Hope for the Risk Reduction of Prostate Cancer

... Urological Association annual meeting in Chicago brings optimism to the prostate cancer community as dutasteride (Avodart), a drug used to treat benign prostatic hyperplasia, has shown to lower by 23 percent the risk of prostate cancer in men with an increased risk of the disease. Men's Health ...

Data Presented at AUA Demonstrate PROVENGE Significantly Prolongs Survival for Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study

... Dendreon is also developing an orally-available small molecule that targets TRPM8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For ...

New Body of Research Suggests Statin Use Benefits Multiple Areas of Urologic Health

... use of statins and non-steroidal anti-inflammatory drugs (NSAIDs) may further decrease the risk of developing lower urinary tract symptoms related to benign prostatic hyperplasia. "These studies add to a growing body of literature supporting the beneficial effects of statins in certain subsets of ...

Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer

... the direction of Dr. Anthony W. Tolcher. "D3263 is a drug candidate that has potential applicability to multiple types of cancer as well as to benign prostatic hyperplasia (BPH)," stated Mark Frohlich, M.D., senior vice president of clinical affairs and chief medical officer of Dendreon. "The ...

Dendreon to Hold a Conference Call Tomorrow at 9:00 AM ET to Discuss Final Results of Phase 3 PROVENGE IMPACT Trial

... Dendreon is also developing an orally-available small molecule that targets TRPM8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For ...

Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)

... announced today that RAPAFLO (TM) (silodosin), the company's new, uniquely selective alpha blocker for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH), is available for patients by prescription. Watson received U.S. Food and Drug Administration (FDA) approval for ...

Neurocrine Announces Top-Line Results From 702 Study (Lilac PETAL Study) of Elagolix for Treatment of Endometriosis Pain

... Our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, anxiety, depression, pain, diabetes, benign prostatic hyperplasia (BPH), irritable bowel syndrome (IBS) and other neurological and endocrine related diseases and disorders. Neurocrine ...

Vantia Therapeutics' Pipeline Continues to Mature

... (defined as waking to void at night) is a common condition, with prevalence increasing markedly with age. It is often the presenting symptom of benign prostatic hypertrophy (BPH) with at least 70% of BPH patients complaining of nocturia. Whilst some symptoms of BPH are successfully addressed by the ...

AndroScience Corporation Announces Phase 2a Study Results on ASC-J9(TM) for the Treatment of Acne

... is currently pursuing androgenetic alopecia (male pattern baldness), and wound healing using topical based formulations; and prostate cancer, benign prostatic hyperplasia, and spinal bulbar muscular atrophy (Kennedy's Disease - a neuron motor disease caused by AR mutation) utilizing systemic based ...

YM BioSciences Announces Milestone Payment For Approval Of Nimotuzumab In The Philippines And Indonesia

... marketing in a number of countries, is significantly differentiated from all other currently marketed EGFR-targeting agents because of a remarkably benign side-effect profile. In more than 3,000 patients treated worldwide, to date, no Grade III/IV rash or radiation dermatitis has been reported and ...

ASGE and The Pancreatic Cancer Action Network Partner to Raise Awareness About Pancreatic Cancer

... to turn pale. It can also cause pain, weight loss, nausea, vomiting, and itchy skin. The symptoms of pancreatic cancer can be confused with those of benign diseases such as arthritis (back pain), gallstones (jaundice) or chronic pancreatitis (pain, diarrhea, weight loss). Unfortunately, by the time most ...

Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium

... Dendreon is also developing an orally-available small molecule that targets Trp-p8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For ...

New International Study Shows Women With Symptomatic Fibroids Delaying Treatment Despite Substantial Burden on Quality of Life

... or medically -- for their fibroids, which means that many women continue to experience symptoms severe enough to affect QoL. Uterine fibroids are benign tumors made up of fibrous and muscular tissue in the uterine wall. They occur in one third of women over age thirty and are a major reason for ...

NCI Funded Clinical Trial to Study Treatment of Breast Cancer Using Cryoablation

... tumor and subsequent pathological evaluation. "Cryoablation has been used effectively for years to treat a number of medical conditions, including benign breast tumors, so it is a natural progression to study its use in the treatment of breast cancer," said Dr Levine. "We are very encouraged about the ...

Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial

... Dendreon is also developing an orally-available small molecule called Trp-p8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For ...

Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial

... Dendreon is also developing an orally-available small molecule called Trp-p8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For ...

Society of Interventional Radiology Applauds Report's Uterine Fibroid Embolization Recommendations

... additional important information about the pelvic organs is found that helps the woman choose her best treatment option. Uterine fibroids are benign tumors that can cause prolonged, heavy menstrual bleeding that can be severe enough to cause anemia or require transfusion; disabling pelvic pain and ...

Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis

... some of the largest pharmaceutical markets in the world including endometriosis, irritable bowel syndrome (IBS), anxiety, depression, pain, diabetes, benign prostatic hyperplasia (BPH) and other neurological and endocrine related diseases and disorders. Neurocrine Biosciences, Inc. news releases are ...

BioVex Announces Regulatory Clearance to Commence a Clinical Study With ImmunoVEX HSV2; A Vaccine Candidate for Genital Herpes

... to become a leading standard of care in the treatment of many solid tumors based on the strength of clinical data generated to date, coupled with a benign side effect profile. BioVex is currently completing a Phase II clinical trial of OncoVEXGM-CSF for melanoma and Phase I/II clinical trials for head ...